Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALB | P02768 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.30 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23797137 | 0.81 | ABL1 (0.46) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL5013964 | 0.81 | ABL1 (0.46) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL6632471 | 0.81 | ABL1 (0.46) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL6744346 | 0.75 | ABL1 (0.41) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL6744345 | 0.75 | ABL1 (0.41) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL22080061 | 0.74 | ABL1 (0.45) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL25813255 | 0.74 | ABL1 (0.45) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL14045693 | 0.74 | ABL1 (0.55) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL9351697 | 0.73 | ABL1 (0.42) | ABL1RIN1LMNAALBALDH1A1 | |
| SCHEMBL9351701 | 0.73 | ABL1 (0.42) | ABL1RIN1LMNAALBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900301-B2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-0586570-B1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-1004593-A2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | RNASE1, RNGTT, NSUN2 | ABL1 4843/4885RIN1 1843/4885LMNA 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.